Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Proteomics International Laboratories Ltd. Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 892.14K | 730.34K | 1.49M | 1.31M | 1.42M |
| Gross Profit | -1.12M | -1.62M | -568.62K | 497.08K | 584.64K |
| EBITDA | -8.40M | -7.55M | -4.56M | -2.77M | -1.70M |
| Net Income | -6.38M | -6.23M | -4.97M | -2.86M | -1.74M |
Balance Sheet | |||||
| Total Assets | 10.88M | 10.08M | 5.40M | 8.60M | 5.55M |
| Cash, Cash Equivalents and Short-Term Investments | 6.64M | 6.03M | 2.11M | 5.60M | 2.37M |
| Total Debt | 316.39K | 64.09K | 0.00 | 69.05K | 132.84K |
| Total Liabilities | 1.63M | 1.75M | 2.00M | 990.19K | 1.12M |
| Stockholders Equity | 9.41M | 8.38M | 3.39M | 7.61M | 4.44M |
Cash Flow | |||||
| Free Cash Flow | -6.00M | -6.91M | -3.67M | -2.41M | -1.97M |
| Operating Cash Flow | -5.59M | -5.69M | -3.54M | -2.21M | -384.51K |
| Investing Cash Flow | -388.02K | -1.17M | -129.46K | -191.00K | -1.59M |
| Financing Cash Flow | 6.59M | 10.77M | 176.10K | 5.64M | 2.82M |
Proteomics International Laboratories Ltd. Technical Analysis
Proteomics International Laboratories Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ¥345.34B | 10.96 | -2.99% | 2.56% | 11.77% | -10.16% | |
56 Neutral | AU$34.63M | ― | -36.95% | ― | ― | 11.11% | |
52 Neutral | AU$76.93M | ― | -131.55% | ― | 12.53% | -11.04% | |
| ― | €47.05M | ― | -151.55% | ― | ― | ― | |
42 Neutral | AU$12.09M | ― | -180.09% | ― | ― | 28.57% | |
40 Underperform | AU$95.43M | ― | ― | ― | -33.01% | ||
34 Underperform | AU$52.03M | ― | -108.26% | ― | ― | 53.41% |
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Laboratories Ltd has announced groundbreaking results for its OxiDx test, which can identify and assess recovery from exercise-induced muscle damage in thoroughbred racehorses. This novel test, published in the journal Veterinary Medicine and Science, offers a simple and effective solution for managing horse recovery post-race, addressing a significant gap in equine veterinary medicine. The OxiDx test, which measures oxidative stress through a dried blood spot, presents a more precise and less invasive alternative to current methods such as MRI and ultrasound. The successful study marks a significant milestone in the commercialisation of the OxiDx test, with plans for an Australian launch in late 2025 and subsequent expansion into the USA.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the quotation of 160,420 fully paid ordinary securities on the ASX, effective July 9, 2025. This move is part of the company’s strategy to enhance its market presence and provide more liquidity to its shareholders, potentially impacting its operational capabilities and market positioning positively.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the cessation of 4,102 employee performance rights due to unmet conditions as of June 30, 2025. This development may affect the company’s employee incentive plans and reflects the challenges in meeting performance targets, which could have implications for its operational strategies and stakeholder confidence.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has released a report detailing the top 20 holders of its options expiring on May 31, 2026, at $0.50. The report highlights that BNP Paribas Noms Pty Ltd holds the largest share at 7.09%, followed by J P Morgan Nominees Australia Pty Limited at 5.56%. The total issued capital is 16,259,055, with the top 20 holders accounting for 38.04% of this capital. This report provides insight into the company’s shareholder structure, which may influence its market strategies and stakeholder engagement.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the application for quotation of new securities on the ASX, specifically listed options set to expire on May 31, 2026. This move is likely to enhance the company’s financial flexibility and could potentially impact its market positioning by attracting new investors and increasing liquidity.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced a $6 million expansion of the WA Proteomics Facility, in collaboration with The University of Western Australia, the WA State Government, and Bioplatforms Australia. This investment will enhance the facility’s capabilities in precision diagnostics, enabling industrial-scale screening for medical and agricultural applications. The initiative aims to establish a nationally accredited platform for protein biomarker analysis, which will support the development of diagnostic tests and improve outcomes in clinical and agricultural settings.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the release of its next-generation PromarkerD test system, a diagnostic tool designed to predict diabetic kidney disease (DKD) in type 2 diabetes patients up to four years before symptoms appear. This advancement, presented at the American Diabetes Association’s Scientific Sessions, marks a significant step towards global commercialization and regulatory expansion, offering a simplified yet accurate method to identify at-risk individuals, thereby enabling early intervention and potentially reducing the progression to severe renal conditions.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has launched its predictive blood test, PromarkerD, in the US at the American Diabetes Association’s Scientific Sessions. This test, which can predict the onset of diabetes-related chronic kidney disease up to four years in advance, is initially available in California. It represents a significant commercial opportunity in the US, aiming to improve patient outcomes and reduce healthcare costs associated with DKD. The launch is part of the company’s broader strategy to engage with healthcare providers and expand its market presence through direct-to-consumer and partner sales avenues.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced a change in the director’s interest, specifically involving Dr. Richard Lipscombe. The change includes the acquisition of additional ordinary shares and options, following shareholder approval at an extraordinary general meeting. This development reflects the company’s ongoing strategic initiatives to enhance its market position and align its leadership’s interests with those of its stakeholders.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has issued 1,351,352 ordinary shares without disclosure under the Corporations Act, complying with relevant legal provisions. This move reflects the company’s strategic financial management and commitment to maintaining transparency, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the issuance of 10,177,982 unquoted securities with an expiration date of May 31, 2026, at an exercise price of $0.50. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing projects, potentially impacting its market positioning by providing additional resources for growth and development.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the issuance of 2,000,000 unquoted equity securities in the form of options, expiring on June 6, 2027, with an exercise price of $0.555. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX, potentially impacting the company’s financial strategy and stakeholder interests by expanding its equity base.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the issuance of 675,674 unquoted equity securities, specifically options expiring on May 31, 2026, with an exercise price of $0.50. This issuance is part of the company’s ongoing financial strategies and may impact its market positioning by potentially increasing its capital base, thereby supporting its operational and strategic initiatives.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the application for the quotation of 1,351,352 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is likely to enhance the company’s market presence by increasing its liquidity and potentially attracting more investors.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the quotation of 20,356,556 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of June 6, 2025. This move is part of previously announced transactions and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities, potentially impacting its stakeholders by increasing liquidity and investment opportunities.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced an update regarding its securities purchase plan (SPP), accepting oversubscriptions as of June 5, 2025. This move indicates strong investor interest and could enhance the company’s financial position, potentially impacting its market strategy and stakeholder value positively.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced a significant expansion of its Share Purchase Plan (SPP) due to overwhelming demand, receiving applications exceeding $7.5 million, far surpassing the initial $1 million target. The company will issue 10,177,982 new options to accommodate all valid applications, thereby increasing its capital structure significantly and enhancing its market position by allowing more stakeholders to participate in its growth.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the publication of clinical validation results for its PromarkerEso blood test, which diagnoses esophageal adenocarcinoma with high accuracy. This test, which offers a non-invasive alternative to current endoscopy procedures, demonstrated 91.4% sensitivity and 98.9% specificity, marking a significant advancement in early detection of this cancer. The commercialization of PromarkerEso is expected to begin in Australia, with plans to expand to other regions. This development could revolutionize the management of esophageal cancer, potentially improving early diagnosis rates and health outcomes for patients globally.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced that all resolutions at their Extraordinary General Meeting were passed by poll. This development signifies strong shareholder support for the company’s strategic initiatives, potentially strengthening its market position and enhancing stakeholder confidence.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced that its subsidiary, OxiDx Pty Ltd, has secured a new patent in China for its OxiDx technology, which measures oxidative stress using a simple fingerprick blood sample. This patent, valid until 2039, extends the company’s intellectual property protection across major markets including the USA, Japan, Europe, China, and Australia. The OxiDx test, which is gaining traction in sectors such as high-performance sports and horse racing, is crucial as oxidative stress is linked to over 70 health conditions, including muscle injuries prevalent in these industries.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd. has announced a Share Purchase Plan following a successful placement of shares to sophisticated and institutional investors, raising approximately $4 million. The funds will be used to launch Promarker tests in Australia and the USA, upgrade systems for clinical diagnostics, and establish laboratory platforms, with the total expected proceeds reaching $5.5 million. The plan offers eligible shareholders the opportunity to purchase additional shares at a discounted price, with the potential to raise an additional $1 million.
Proteomics International Laboratories Ltd has announced a correction to the date of its upcoming Extraordinary General Meeting, now scheduled for Friday, 30 May 2025. The company encourages shareholders to participate by lodging proxy votes online and updating their communication preferences to receive future documents electronically, reflecting a move towards more digital engagement with stakeholders.
Proteomics International Laboratories Ltd has announced an Extraordinary General Meeting scheduled for 30 May 2025. The company is encouraging shareholders to participate by lodging their proxy votes online, emphasizing the importance of digital communication and efficiency. This meeting is a significant event for stakeholders, as it may involve decisions impacting the company’s strategic direction and operations.
Proteomics International Laboratories Ltd has issued 10,810,811 ordinary shares without disclosure under the Corporations Act, as per their notice under Section 708A(5)(e). The company has confirmed compliance with relevant provisions of the Corporations Act and stated that there is no excluded information required to be disclosed. This issuance reflects the company’s ongoing operations and compliance, potentially impacting its financial positioning and stakeholder interests.
Proteomics International Laboratories Ltd announced the issuance of 5,405,399 unquoted securities, set to expire on May 31, 2026, with an exercise price of $0.50. This issuance is part of previously announced transactions and is not intended to be quoted on the ASX. The move may impact the company’s financial structure and provide additional capital for its ongoing projects.
Proteomics International Laboratories Ltd has announced the application for quotation of 10,810,811 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of previously announced transactions and is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning positively.
Proteomics International Laboratories Ltd has issued a prospectus for the offer of new options, targeting placement participants, directors, key management personnel, joint lead managers, and SPP participants. This strategic move is aimed at raising capital, which could enhance the company’s operational capabilities and market position. The options are considered highly speculative, and the company advises potential investors to seek professional advice before participating. The offer is limited to applicants within Australia and New Zealand, aligning with the company’s continuous disclosure obligations under the Corporations Act.
Proteomics International Laboratories Ltd announced significant advancements in its operations, including the launch of the PromarkerD predictive test for diabetic kidney disease in Australia, which outperforms conventional tests. The company also opened a CLIA certified reference laboratory in California and secured a new Australian patent for its OxiDx technology. These developments are part of Proteomics International’s strategy to commercialize its suite of precision diagnostic tests, leveraging the growing telehealth market and direct-to-consumer healthcare trends to enhance its industry positioning and offer scalable, cost-effective diagnostic solutions.
Proteomics International Laboratories Ltd has announced a proposed issue of securities, including options expiring in May 2026 and ordinary fully paid shares, with a total of 16,216,216 securities to be issued. This move is likely aimed at raising capital to support the company’s ongoing research and development efforts, potentially enhancing its market position and providing value to stakeholders.
Proteomics International Laboratories Ltd has successfully secured A$4.5 million through a placement to institutional and sophisticated investors to support the commercial launch of its Promarker diagnostic tests in the US and Australia. The funds will be used to launch PromarkerD, PromarkerEso, and PromarkerEndo tests, upgrade systems for clinical diagnostics in Australia, and establish laboratory platforms in the USA, enhancing the company’s market positioning in precision diagnostics.
Proteomics International Laboratories Ltd has requested a trading halt on its securities on the Australian Securities Exchange as it prepares to release an announcement regarding a capital raise and subsequent issue of securities. This move indicates a strategic financial maneuver that could impact the company’s market operations and potentially affect its stakeholders.